Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of ELX/TEZ/IVA in Cystic Fibrosis Patients 6 Years and Older
NCT04183790Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2020
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of elexacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoints: Treatment Emergent Adverse Events at Week 196 and Serious Adverse Events at Week 196. Started Feb 2020; status: completed.
02
Drugs
elexacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04183790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04183790.